166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy
HB Breitz, RE Wendt, MS Stabin, S Shen… - Journal of Nuclear …, 2006 - Soc Nuclear Med
166Ho-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylene-phosphonate (DOTMP)
is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces …
is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces …
Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166Ho-DOTMP
H Breitz, R Wendt, M Stabin, L Bouchet… - Cancer Biotherapy and …, 2003 - liebertpub.com
A study was undertaken to determine the maximum tolerated dose of 166Ho-DOTMP that
could be administered safely, without negatively impacting marrow re-engraftment, in …
could be administered safely, without negatively impacting marrow re-engraftment, in …
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation
JG Rajendran, JF Eary, W Bensinger… - Journal of nuclear …, 2002 - Soc Nuclear Med
Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1, 4, 7, 10-
tetraazacyclododecane-1, 4, 7, 10-tetramethylene-phosphonic acid (DOTMP) and were a …
tetraazacyclododecane-1, 4, 7, 10-tetramethylene-phosphonic acid (DOTMP) and were a …
A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical
J Simón, RK Frank, DK Crump, WD Erwin… - Nuclear medicine and …, 2012 - Elsevier
INTRODUCTION: The therapeutic potential of the bone-seeking radiopharmaceutical
153Sm-labeled 1, 4, 7, 10-tetraazacyclododecanetetramethylenephos… acid (153Sm …
153Sm-labeled 1, 4, 7, 10-tetraazacyclododecanetetramethylenephos… acid (153Sm …
Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases
BT Hsieh, JF Hsieh, SC Tsai, WY Lin, SJ Wang… - Nuclear medicine and …, 1999 - Elsevier
In the past, many diphosphonates were introduced as bone scan radiopharmaceuticals. In
addition, diphosphonates have been labeled with beta-emitted isotopes and developed into …
addition, diphosphonates have been labeled with beta-emitted isotopes and developed into …
Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases
K Liepe, R Hliscs, J Kropp, R Runge… - Journal of Nuclear …, 2003 - Soc Nuclear Med
188Re-Hydroxyethylidene diphosphonate (188Re-HEDP) was used in previous studies for
the palliative treatment of metastatic bone pain. However, the kinetic and radiation-absorbed …
the palliative treatment of metastatic bone pain. However, the kinetic and radiation-absorbed …
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
S Giralt, W Bensinger, M Goodman, D Podoloff, J Eary… - Blood, 2003 - ashpublications.org
Abstract Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-
tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically …
tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically …
Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease
W Brenner, WU Kampen, AM Kampen… - Journal of Nuclear …, 2001 - Soc Nuclear Med
The aim of this study was to introduce a new quantification method for 153Sm-
ethylenediaminetetramethylenephosphonate (EDTMP) and 186Re-(tin) 1, 1 …
ethylenediaminetetramethylenephosphonate (EDTMP) and 186Re-(tin) 1, 1 …
Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation
Background Designing ideal radiopharmaceuticals for use as bone pain palliative agents
requires the use of a moderate energy β− emitter as the radionuclide and a …
requires the use of a moderate energy β− emitter as the radionuclide and a …
Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs
JN Bryan, D Bommarito, DY Kim… - Journal of nuclear …, 2009 - Soc Nuclear Med
Bone-seeking radiopharmaceuticals have been used to effectively treat cancer arising from
and metastasizing to bone in humans and dogs. The rate of complete tumor control is low …
and metastasizing to bone in humans and dogs. The rate of complete tumor control is low …